X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
http://www.pharmatimes.com/news/eu_marketing_authorisation_change_for_maviret_1328393
https://www.prnewswire.com/news-releases/abbvie-receives-positive-chmp-opinion-for-maviret-glecaprevirpibrentasvir-to-shorten-treatment-duration-to-eight-weeks-in-genotype-3-treatment-naive-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis-300996801.html
https://www.in-pharmatechnologist.com/Article/2019/09/30/AbbVie-receives-approval-HCV-treatment
https://endpts.com/fda-clears-shorter-treatment-regimen-for-abbvies-hep-c-treatment-mavyret-will-patients-benefit/
https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-adults-and-children-all-genotypes-hepatitis-c-and-compensated-cirrhosis
https://www.prnewswire.com/news-releases/abbvie-receives-fda-approval-of-mavyret-glecaprevirpibrentasvir-to-shorten-treatment-duration-to-eight-weeks-for-treatment-naive-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis-across-all-genotypes-300926647.html
https://www.fiercepharma.com/pharma/gilead-s-authorized-hcv-generics-now-own-over-20-market
https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and
https://www.biopharmadive.com/news/fda-safety-warning-hepatitis-c-drugs-patient-deaths/561891/
http://www.pharmatimes.com/news/us_approves_first_all-genotype_treatment_for_pediatric_hepatitis_c_1286539
https://www.prnewswire.com/news-releases/fda-approves-first-treatment-for-all-genotypes-of-hepatitis-c-in-pediatric-patients-300840980.html
https://msfaccess.org/msf-access-campaign-analysis-mpp-licence-agreement-abbvie-glecaprevirpibrentasvir-gp
https://www.fiercepharma.com/marketing/gilead-airs-first-hep-c-epclusa-campaign-even-as-its-own-generics-way
http://www.pmlive.com/pharma_news/nhs_england_sees_off_abbvies_hep_c_legal_challenge_1275737
https://www.fiercepharma.com/marketing/abbvie-highlights-mavyret-s-8-week-advantage-new-ad-campaign-as-it-continues-its-hep-c
https://www.prnewswire.com/news-releases/abbvies-mavyret-glecaprevirpibrentasvir-shows-high-virologic-cure-rates-in-treatment-naive-hepatitis-c-patients-with-compensated-cirrhosis-300749284.html
https://www.prnewswire.com/news-releases/the-medicines-patent-pool-signs-licence-with-abbvie-to-expand-access-to-key-hepatitis-c-treatment-glecaprevir-pibrentasvir-889601742.html
https://www.fiercepharma.com/pharma/gilead-beats-q3-forecasts-as-hiv-portfolio-soars-but-it-enough-to-combat-falling-hcv-sales
https://www.raps.org/news-and-articles/news-articles/2018/9/fda-issues-54-new-and-revised-product-specific-gui?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2013%20September
https://www.fiercepharma.com/pharma/express-scripts-bars-48-drugs-for-2019-biting-abbvie-gilead-boehringer-and-more
https://www.fiercepharma.com/pharma-asia/gilead-wins-chinese-approval-for-epclusa-but-emerging-market-getting-crowded
https://www.fiercepharma.com/pharma/hep-c-still-under-fire-gilead-a-trough-year-cfo-says
https://www.fiercepharma.com/pharma/abbvie-blows-hep-c-forecasts-out-water-as-mavyret-snaps-up-share
https://www.fiercepharma.com/corporate/gilead-strikes-back-at-gsk-positive-hiv-head-to-head-trial-data
https://www.fiercepharma.com/financials/gilead-s-hep-c-guidance-comes-far-short-expectations-as-abbvie-s-mavyret-scoops-up-share
http://www.prnewswire.com/news-releases/abbvie-announces-approval-of-maviret-glecaprevirpibrentasvir-for-the-treatment-of-chronic-hepatitis-c-in-all-major-genotypes-gt1-6-in-japan-300526493.html
https://www.pharmacompass.com/pdf/news/abbvies-maviret-glecaprevir-pibrentasvir-receives-approval-in-europe-1503029648.pdf
Market Place
Share 
